Patents by Inventor Erich Gulbins

Erich Gulbins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200362057
    Abstract: Provided herein are methods of treating major depressive disorder (MDD) in a subject in need thereof, the method including administering to the subject an effective amount of an active agent that reduces an amount of ceramide in a peripheral compartment of the subject. Also provided are methods of reducing ceramide levels in neuronal tissue of a subject suffering from MDD, the method including peripherally administering to the subject an effective amount of an active agent that modulates ceramide; as well as methods of identifying a candidate agent to treat MDD.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 19, 2020
    Inventor: Erich Gulbins
  • Publication number: 20200268686
    Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
    Type: Application
    Filed: May 11, 2020
    Publication date: August 27, 2020
    Inventors: Erich Gulbins, Karl Sebastian Lang, Judith Bezgovsek
  • Publication number: 20200254153
    Abstract: Methods for applying a coating to a surface of a substrate for inhibition and prevention of implant-associated complications (including implant-associated infections), methods for inhibiting and preventing implant-associated complications (including implant-associated infections), implant-associated infection inhibiting coatings, and coated devices are provided. Coating processes include a) providing a saturated or supersaturated solution of an antibiotic in a fast-evaporating or medium-evaporating organic solvent; b) coating the surface of the substrate with at least one application of solution, each application followed directly by a solvent evaporation period.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 13, 2020
    Inventors: Aaron Seitz, Michael Edwards, Erich Gulbins, Ryan Gobble
  • Patent number: 10688065
    Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 23, 2020
    Assignee: Harbins Ruhr Bioscience, Inc.
    Inventors: Erich Gulbins, Karl Sebastian Lang, Judith Bezgovsek
  • Publication number: 20200113850
    Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
    Type: Application
    Filed: September 30, 2019
    Publication date: April 16, 2020
    Inventors: Erich Gulbins, Karl Sebastian Lang, Judith Bezgovsek
  • Patent number: 10568945
    Abstract: A pharmaceutical composition containing (1) a therapeutically effective amount of hepatocyte-derived exosomes; and (2) a pharmaceutically-acceptable carrier is provided. Also provided herein is a method of inducing liver regeneration in a patient in need thereof, the method including administering to the patient a therapeutic amount of hepatocyte-derived exosomes, wherein liver regeneration is induced. Methods for up-regulating synthesis of synthesis of sphingosine-1-phosphate (S1P) in a hepatocyte by contacting the hepatocyte with at least one vesicle containing sphingosine kinase 2, and, optionally, ceramide and neutral ceramidase, are also disclosed.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 25, 2020
    Assignee: University of Cincinnati
    Inventors: Alex B. Lentsch, Michael J. Edwards, Erich Gulbins
  • Publication number: 20190151424
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 23, 2019
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Patent number: 10159724
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: December 25, 2018
    Assignees: Icahn School of Medicine at Mount Sinai, Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Publication number: 20180353656
    Abstract: Methods for applying a sphingolipid aggregate coating to a surface of a substrate for inhibition and prevention of biofilm growth, methods for inhibiting and preventing biofilms, biofilm-inhibiting coatings and coated devices are provided. Coating processes include suspending an amount of sphingolipid in a medium-to-fast-evaporating organic solvent; b) applying energy to the suspension sufficient to create a colloidal dispersion of sphingolipid in the solvent; c) heating the dispersion sufficient to create a solution; and d) coating the surface of the substrate with at least one application of solution, each application followed directly by a complete solvent evaporation period. The resulting coatings exhibit aggregate architectures particularly effective for inhibition and prevention of biofilms.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 13, 2018
    Inventors: Aaron Seitz, Michael J. Edwards, Erich Gulbins
  • Publication number: 20170295776
    Abstract: Methods, additive kits and storage compositions for decreasing the deleterious effects of storage on pRBCs, for improving the aging process of stored pRBCs, and for preventing or ameliorating patient comorbidities following the transfusion or infusion of stored blood based on inhibiting acid sphingomyelinase during storage are provided.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 19, 2017
    Inventors: Richard S. Hoehn, Peter L. Jernigan, Alex L. Chang, Charles C. Caldwell, Alex Lentsch, Michael J. Edwards, Erich Gulbins, Timothy A. Pritts
  • Publication number: 20170020998
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Patent number: 9492514
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: November 15, 2016
    Assignees: Icahn School of Medicine at Mount Sinai, Universitaet Duisberg-Essen, Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Publication number: 20150306189
    Abstract: A pharmaceutical composition containing (1) a therapeutically effective amount of hepatocyte-derived exosomes; and (2) a pharmaceutically-acceptable carrier is provided. Also provided herein is a method of inducing liver regeneration in a patient in need thereof, the method including administering to the patient a therapeutic amount of hepatocyte-derived exosomes, wherein liver regeneration is induced. Methods for up-regulating synthesis of synthesis of sphingosine-1-phosphate (S1P) in a hepatocyte by contacting the hepatocyte with at least one vesicle containing sphingosine kinase 2, and, optionally, ceramide and neutral ceramidase, are also disclosed.
    Type: Application
    Filed: April 27, 2015
    Publication date: October 29, 2015
    Inventors: Alex B. Lentsch, Michael J. Edwards, Erich Gulbins
  • Publication number: 20150258043
    Abstract: Methods of preventing or treating bacterial infections, including but not limited to Pseudomonas aeruginosa infections, by administering sphingoid long chain bases (LCB) are provided. The invention further relates to the use of sphingoid long chain bases, or pharmaceutical composition comprising same, for the treatment of lung diseases or disorders such as cystic fibrosis and chronic obstructive pulmonary disease.
    Type: Application
    Filed: October 15, 2013
    Publication date: September 17, 2015
    Inventors: Anthony Futerman, Yael Pewzner-Jung, Erich Gulbins
  • Publication number: 20150125439
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 7, 2015
    Applicant: Universitatsstrasse 2
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Publication number: 20110059949
    Abstract: The invention relates to the use of inhibitors of acid sphingomyelinase and/or of inhibitors of products of the reaction catalyzed by this enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferrably neutralizing antibodies and/or antidepressants, especially tricyclic and/or tetracyclic antidepressants, are used as inhibitors.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 10, 2011
    Inventor: Erich Gulbins
  • Publication number: 20100285139
    Abstract: A pharmaceutical composition for prophylaxis and/or treatment of infections and/or infectious diseases occurring in cystic fibrosis includes at least one antidepressant; at least one dispersant; and at least one pharmaceutically tolerable carrier material.
    Type: Application
    Filed: December 22, 2008
    Publication date: November 11, 2010
    Applicant: CYCNAD GMBH & CO., KG
    Inventor: Erich Gulbins
  • Patent number: 7812015
    Abstract: The invention relates to the use of inhibitors of acid sphingomyelinase and/or of inhibitors of products of the reaction catalyzed by this enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferrably neutralizing antibodies and/or antidepressants, especially tricyclic and/or tetracyclic antidepressants, are used as inhibitors.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: October 12, 2010
    Inventor: Erich Gulbins
  • Publication number: 20050209219
    Abstract: The invention relates to the use of inhibitors of acid sphingomyelinase and/or inhibitors of products of the reaction catalysed by said enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferably neutralising antibodies and/or anti-depressants, especially tricyclic and/or tetracyclic and depressants, are used as inhibitors.
    Type: Application
    Filed: August 21, 2003
    Publication date: September 22, 2005
    Inventor: Erich Gulbins
  • Patent number: 6552116
    Abstract: A multi-stage emulsion polymer containing at least one first domain having a glass transition temperature Tg of from −10 to +40° C. and at least one second domain having a Tg of from +50 to 120° C., the weight ratio of the first domain to the second domain being within the range from 90:10 to 50:50. The first and/or the second domain containing from 0.1 to 10% by weight of a nitrogen-coutaining adhesion monomer and the first domain containing at least 10% by weight of vinyl aromatic compounds and/or the second domain containing at least 15% by weight of vinyl aromatic compounds and/or C4 to C12 alkylmethacrylates.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: April 22, 2003
    Assignee: BASF Aktiengesellchaft
    Inventors: Joachim Pakusch, Uwe Dittrich, Harald Röckel, Alan Smith, Erich Gulbins, Li Zhuo